January 9, 2026by Brittnay
09 January 2026

A Shared Commitment to the Stomach Cancer Community

Supporting patients and families affected by stomach cancer remains at the heart of this work. We encourage our community to stand with us in support of those impacted by stomach […]

Articles
A Shared Commitment to the Stomach Cancer Community
This is the default image
November 21, 2023by brittnay
21 November 2023

2023.11.21 – FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2- Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

RAHWAY, N.J., Nov. 16, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has […]

Articles
2023.11.21 – FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2- Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is the default image
November 14, 2023by brittnay
14 November 2023

November 14, 2023 – November marks national stomach cancer awareness month

(WENY) — November marks national stomach cancer awareness month with new cases affecting roughly 15,000 men and 10,000 women in 2023. The most common type of stomach cancer is Adenocarcinoma however there are other […]

Articles
November 14, 2023 – November marks national stomach cancer awareness month
This is the default image
November 14, 2023by brittnay
14 November 2023

November 14, 2023 – FDA OKs PD-L1 pharmDx for Gastric and GEJ Cancer

The PD-L1 IHC 22C3 pharmDx companion diagnostic tool is now FDA-approved to aid in the identification of patients with gastric or GEJ adenocarcinoma for whom pembrolizumab is a suitable treatment, […]

Articles
November 14, 2023 – FDA OKs PD-L1 pharmDx for Gastric and GEJ Cancer
This is the default image
October 25, 2023by brittnay
25 October 2023

October 20, 2023 – KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in […]

Articles
October 20, 2023 – KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is the default image
October 25, 2023by brittnay
25 October 2023

October 20, 2023 – Pembrolizumab increases response in resectable gastric, gastroesophageal junction cancers

MADRID — Pembrolizumab with chemotherapy before and after surgery increased pathologic complete response among patients with locally advanced gastric or gastroesophageal junction cancer, according to findings presented at ESMO Congress. […]

Articles
October 20, 2023 – Pembrolizumab increases response in resectable gastric, gastroesophageal junction cancers
This is the default image
October 12, 2023by brittnay
12 October 2023

October 11, 2023 – Patients with Advanced Gastric, Esophageal Cancers Maintain Quality of Life with Opdivo

Patients with advanced/metastatic non–human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC) and treated with Opdivo (nivolumab) and chemotherapy maintained their health-related quality of […]

Articles
October 11, 2023 – Patients with Advanced Gastric, Esophageal Cancers Maintain Quality of Life with Opdivo
This is the default image
September 5, 2023by brittnay
05 September 2023

September 2, 2023 – ENHERTU® Granted Two Breakthrough Therapy Designations In U.S. For Patients Across Multiple HER2 Expressing Cancers

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 […]

Articles
September 2, 2023 – ENHERTU® Granted Two Breakthrough Therapy Designations In U.S. For Patients Across Multiple HER2 Expressing Cancers
This is the default image
July 5, 2023by brittnay
05 July 2023

July 3, 2023 – High prevalence of vitamin B-12 deficiency before and early after gastrectomy in patients with gastric cancer

Gastrectomy causes vitamin B-12 deficiency since vitamin B-12 requires gastric acid and intrinsic factor for its absorption. Vitamin B-12 deficiency is considered to develop years after gastrectomy because of large […]

Articles
July 3, 2023 – High prevalence of vitamin B-12 deficiency before and early after gastrectomy in patients with gastric cancer